Financial Markets collage Northcote Internet Logo
transparent spacer
transparent spacer
 >   > 
transparent spacer
 
curve on page transparent spacer
Northcote Internet Ltd provide Investor Relations Webcasting. Click Here
 
transparent spacer transparent spacer transparent spacer transparent spacer
transparent spacer Home menu end curves
Newsletter
transparent spacer
transparent spacer About Us menu end curves
transparent spacer
transparent spacer Donations menu end curves
transparent spacer
transparent spacer Registrars menu end curves
transparent spacer
transparent spacer Spread Betting menu end curves
transparent spacer
transparent spacer Submit links menu end curves
transparent spacer
transparent spacer transparent spacer
transparent spacer transparent spacer transparent spacer
transparent spacer
transparent spacer
navigation curves Home navigation curves navigation curves By Index navigation curves navigation curves By Sector navigation curves navigation curves Alphabetically navigation curves navigation curves Search navigation curves navigation curves My Portfolio navigation curves
 >  > 
 
Follow northcote_b on Twitter
AstraZeneca
transparent spacer
transparent spacer
transparent spacer
Company Information
Address: Level 9 2 Kingdom Street
London
W2 6BD
Index: To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.
Tel: +44 (0)20 7604 8000 Sector:
Fax: +44 (0)20 7604 8270
E-Mail: IR@astrazeneca.com Epic:
Secretary: Adrian Kemp    
Registrar: Equiniti Ltd Updated: 9/02/2015

News from RSS Feed

Sat, 29 Aug 2015 08:30:00 +0100

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.

Company Overview

AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives

 
Annual Reports
Description Report Date Published Current  
bullet point Annual Report 2014 in PDF 31/12/2014 5/02/2015 Yes  
bullet point Annual Report 2013 in PDF 31/12/2013 6/02/2014 No  
bullet point Annual Report 2012 in PDF 31/12/2012 31/01/2013 No  
bullet point Annual Report 2011 in PDF 31/12/2011 2/02/2012 No  
bullet point Annual Report 2010 in PDF 31/12/2010 27/01/2011 No  
bullet point Annual Report 2009 in PDF 31/12/2009 28/01/2010 No  
bullet point Annual Report 2008 in PDF 31/12/2008 29/01/2009 No  
bullet point Annual Report 2007 in PDF 31/12/2007 31/01/2008 No  
 
Interim Reports
Description Report Date Published Current  
bullet point Interim Results 2014 in PDF 30/06/2014 31/07/2014 Yes  
bullet point Interim Results 2013 in PDF 30/06/2013 1/08/2013 No  
bullet point Interim Results 2012 in PDF 30/06/2012 26/07/2012 No  
 
Other Links
Description
bullet point Home
bullet point Site Map
bullet point Investor Relations
bullet point Events Calendar
bullet point Results Index
bullet point Press Releases
bullet point Presentations
bullet point Contacts
bullet point RSS News Feed
       
Dividend History
Type Payment Date Dividend
Interim 15/09/2014 53.1 p
Interim 24/03/2014 116.8 p
Interim 16/09/2013 59.2 p
Interim 18/03/2013 120.5 p
Interim 10/09/2012 58.1 p
Interim 19/03/2012 123.6 p
Interim 12/09/2011 51.9 p
Interim 14/03/2011 116.7 p
Interim 13/09/2010 44.9 p
Interim 15/03/2010 105.4 p
Interim 14/09/2009 0.59 c USD
Interim 14/09/2009 27.8 p
Interim 14/09/2009 36 p
Interim 16/03/2009 104.8 p
Interim 15/09/2008 27.8 p
Interim 17/03/2008 67.7 p
Interim 17/09/2007 25.3 p
Interim 19/03/2007 63 p
Interim 18/09/2006 26.6 p
Interim 20/03/2006 51.8 p
Interim 19/09/2005 21.9 p
Interim 21/03/2005 34.3 p
Interim 20/09/2004 16 p
Interim 6/04/2004 29.4 p
Interim 6/10/2003 15.9 p
Interim 7/04/2003 28.5 p
Interim 7/10/2002 14.7 p
Interim 8/04/2002 33.2 p
Interim 5/10/2001 16.1 p
Interim 9/04/2001 32.1 p
Interim 23/10/2000 15.3 p
Interim 17/04/2000 29.1 p
Interim 25/10/1999 14.2 p

News from RSS Feed

Sat, 29 Aug 2015 08:30:00 +0100

AstraZeneca to present further research into long-term prevention of cardiovascular events for patients with a history of heart attack at ESC Congress 2015

Over 20 scientific abstracts from AstraZeneca’s cardiovascular and metabolic disease portfolio will be presented at this year’s European Society of Cardiology (ESC) Congress 2015 in London, including five oral presentations. Data being presented will focus on the early management of Acute Coronary Syndromes (ACS) and long-term secondary prevention of atherothrombotic events in patients who have previously suffered a heart attack.
Mon, 24 Aug 2015 06:50:47 +0100

AstraZeneca appoints Dr Sean Bohen as Executive Vice President of Global Medicines Development and Chief Medical Officer

AstraZeneca today announced the appointment of Sean Bohen MD, PhD, as Executive Vice President of Global Medicines Development and Chief Medical Officer. He will join the company on 15 September.
Mon, 24 Aug 2015 06:49:00 +0100

AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial

AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals, Inc. to evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in combination with durvalumab in multiple solid tumours.
Mon, 10 Aug 2015 08:00:00 +0100

Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases.
Thu, 6 Aug 2015 07:00:00 +0100

AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments

AstraZeneca and Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, today announced that they have entered into a licensing agreement under which AstraZeneca will acquire exclusive global rights to develop, manufacture and commercialise the adenosine A2A receptor antagonist, HTL-1071, a small molecule immuno-oncology candidate, and potential additional A2A receptor-blocking compounds. AstraZeneca will explore the assets across a range of cancers, including in combination with its existing portfolio of immunotherapies.
Wed, 5 Aug 2015 07:00:00 +0100

MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer

AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive clinical trial collaboration with Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer. The Phase I/II study will evaluate the safety and efficacy of MedImmune’s investigational anti-PDL1 immune checkpoint inhibitor, durvalumab (MEDI4736), in combination with mocetinostat, Mirati’s investigational spectrum-selective histone deacetylase (HDAC) inhibitor.
Mon, 3 Aug 2015 07:00:00 +0100

AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases

AstraZeneca and Isis Pharmaceuticals, Inc. today announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases. The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca’s strategic approach in these therapeutic areas using novel RNA-targeted treatments. It also enables Isis Pharmaceuticals to extend use of its antisense technology to diseases of the kidney.
Thu, 30 Jul 2015 06:58:00 +0100

AstraZeneca PLC H1 2015 results

“We made good progress in the period, delivering a robust underlying business performance. This represents six successive quarters of top-line growth. The initiatives introduced to increase efficiency are starting to reduce SG&A costs, supporting our continued strategic investment in science and the acceleration of our pipeline which has positive momentum across all key areas."
Mon, 27 Jul 2015 07:00:00 +0100

AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa

AstraZeneca today announced that it has entered into a definitive agreement with Genzyme to divest Caprelsa® (vandetanib), a rare disease medicine.
Wed, 22 Jul 2015 06:24:56 +0100

AstraZeneca provides update on selumetinib in uveal melanoma

AstraZeneca provides update on selumetinib in uveal melanoma
To continue showing the FTSE index and sector information we need a license from FTSE International Limited. Will anyone sponsor us to return this data to the site.


transparent spacer